Results from Tier 3 of Delphi
| Domain | Instrument | Acceptance in | |
|---|---|---|---|
| Dyspnoea | Borg Dyspnea Index | CTD-ILD | IPF |
| MRC Breathlessness (Chronic Dyspnea) Scale or the Modified MRC Dyspnea Scale | CTD-ILD | IPF | |
| Borg Dyspnea Index pre and post exercise | CTD-ILD | – | |
| HRQoL | Medical Outcomes Trust Short Form 36 health survey | CTD-ILD | IPF |
| St George's Dyspnoea Respiratory Questionnaire | – | IPF | |
| Visual analogue scale of Patient Assessment of Disease Activity | CTD-ILD | IPF | |
| Ability to carry out activities of daily living | CTD-ILD | – | |
| Health Assessment Questionnaire Disability Index | CTD-ILD | – | |
| Lung imaging | Extent of honeycombing on HRCT | CTD-ILD | IPF |
| Extent of reticulation on HRCT | – | IPF | |
| Extent of ground glass opacities on HRCT | CTD-ILD | – | |
| Overall extent of ILD on HRCT | CTD-ILD | IPF | |
| Lung physiology/function | Supplemental oxygen requirement | CTD-ILD | IPF |
| FVC on spirometry | CTD-ILD | IPF | |
| Diffusion capacity of lung for carbon monoxide | CTD-ILD | IPF | |
| 6MWT with maximal desaturation on pulse oximetry | CTD-ILD | IPF | |
| 6MWT for distance | – | IPF | |
| Survival | Time to decline in FVC | CTD-ILD | IPF |
| Progression-free survival | CTD-ILD | IPF | |
| Time to death | – | IPF | |
| Medications | Increase or decrease in glucocorticoids | CTD-ILD | IPF |
| Increase or decrease in concomitant immune suppressive agents | CTD-ILD | IPF | |
6MWT, 6 min walk test; CTD-ILD, connective tissue disease associated interstitial lung disease; FVC, forced vital capacity; HRCT, high-resolution CT; IPF, idiopathic pulmonary fibrosis; HRQoL, health-related quality of life; MRC, Medical Research Council.